Gliclazide modified release: a critical review of pharmacodynamic, metabolic, and vasoprotective effects

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023 · see citing works

Glucose clamp technique: a method for quantifying insulin secretion and resistance.

DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · see citing works

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · see citing works

Type 2 diabetes mellitus

DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611 · see citing works

Pathogenesis of NIDDM. A balanced overview.

DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085 · see citing works

Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris

Thompson, S. G., Kienast, J., Pyke, S., Haverkate, F., & van de Loo, J. C. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321003 · Cited by 1,819 · see citing works

Measurement of Plasma Glucose, Free Fatty Acid, Lactate, and Insulin for 24 h in Patients With NIDDM

Reaven, G. M., Hollenbeck, C., Jeng, C.-Y., Wu, M. S., & Chen, Y.-D. I. (1988) · Diabetes · doi:10.2337/diab.37.8.1020 · Cited by 753 · see citing works

A desktop guide to Type 2 diabetes mellitus

European Diabetes Policy Group, 1. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00166.x · Cited by 670 · see citing works

ATP-sensitive K+ channels and insulin secretion: their role in health and disease

Ashcroft, F., & Gribble, F. (1999) · Diabetologia · doi:10.1007/s001250051247 · Cited by 435 · see citing works

Impact of Dosage Frequency on Patient Compliance

Paes, A. H. P., Bakker, A., & Soe-Agnie, C. J. (1997) · Diabetes Care · doi:10.2337/diacare.20.10.1512 · Cited by 411 · see citing works

United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy

(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00001 · Cited by 385 · see citing works

Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.

Gribble, F. M., Tucker, S. J., Seino, S., & Ashcroft, F. M. (1998) · Diabetes · doi:10.2337/diabetes.47.9.1412 · Cited by 263 · see citing works

Gliclazide

Palmer, K. J., & Brogden, R. N. (1993) · Drugs · doi:10.2165/00003495-199346010-00007 · Cited by 191 · see citing works

Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM

Reaven, G. M., Hollenbeck, C., Jeng, C. Y., et al. (1988) · Diabetes · doi:10.2337/diabetes.37.8.1020 · Cited by 183 · see citing works

Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease - preterax and diamicron MR controlled evaluation

Available, N. A. N. (2001) · Diabetologia · doi:10.1007/s001250100612 · Cited by 180 · see citing works

In vitro and in vivo antioxidant properties of gliclazide

O’Brien, R. C., Luo, M. B., Balazs, N. D. H., & Mercuri, J. (2000) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(00)00084-2 · Cited by 140 · see citing works

Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy

Hosker, J. P., Rudenski, A. S., Burnett, M. A., Matthews, D. R., & Turner, R. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90064-4 · Cited by 125 · see citing works

Normalization of Plasma Lipid Peroxides, Monocyte Adhesion, and Tumor Necrosis Factor-α Production in NIDDM Patients After Gliclazide Treatment

Desfaits, A.-C., Serri, O., & Renier, G. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.487 · Cited by 123 · see citing works

Differential sensitivity of beta-cell and extrapancreatic K ATP channels to gliclazide

Gribble, F. M., & Ashcroft, F. M. (1999) · Diabetologia · doi:10.1007/s001250051236 · Cited by 107 · see citing works

The Glucose Clamp Technique

Waldh�usl, W. K. (2015) · Frontiers in diabetes · doi:10.1159/000422655 · Cited by 91 · see citing works

Gliclazide: a general free radical scavenger

Scott, N., Jennings, P. E., Brown, J. B., et al. (1991) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(91)90069-t · Cited by 91 · see citing works

Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: Clinical assessment

Jennings, P. E., Scott, N., Saniabadi, A. R., et al. (1992) · Metabolism · doi:10.1016/0026-0495(92)90093-p · Cited by 90 · see citing works

Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells

Omi, H., Okayama, N., Shimizu, M., Okouchi, M., Ito, S., Fukutomi, T., & Itoh, M. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00163-5 · Cited by 87 · see citing works

Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice

Guillausseau, P.-J. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70011-3 · Cited by 82 · see citing works

Gliclazide protects pancreatic β-cells from damage by hydrogen peroxide

Kimoto, K., SUZUKI, K. S., Kizaki, T., Hitomi, Y., Ishida, H., Katsuta, H., Itoh, E., Ookawara, T., Suzuki, K., Honke, K., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00310-3 · Cited by 79 · see citing works

Glimepiride block of cloned β‐cell, cardiac and smooth muscle KATP channels

Song, D., & Ashcroft, F. M. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704062 · Cited by 76 · see citing works

Acute and steady-state insulin responses to glucose in nonobese diabetic subjects

Lerner, R. L., & Porte, D. (1972) · Journal of Clinical Investigation · doi:10.1172/jci106963 · Cited by 76 · see citing works

Gliclazide improves anti‐oxidant status and nitric oxide‐mediated vasodilation in Type 2 diabetes

Fava, D., Cassone-Faldetta, M., Laurenti, O., Luca, O. D., Ghiselli, A., & MATTIA, G. D. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00762.x · Cited by 75 · see citing works

Gliclazide Modified Release

McGavin, J. K., Perry, C. M., & Goa, K. L. (2002) · Drugs · doi:10.2165/00003495-200262090-00010 · Cited by 61 · see citing works

Complete bioavailability and lack of food‐effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers

Delrat, P., Paraire, M., & Jochemsen, R. (2002) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.303 · Cited by 58 · see citing works

Diamicron®MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study

Drouin, P. (2000) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(00)00086-6 · Cited by 46 · see citing works

Structural Basis for the Interference Between Nicorandil and Sulfonylurea Action

Reimann, F. M., Ashcroft, F. M., & Gribble, F. M. (2001) · Diabetes · doi:10.2337/diabetes.50.10.2253 · Cited by 43 · see citing works

Antiaggregatory activity of hypoglycaemic sulphonylureas

Siluk, D., Kaliszan, R., Haber, P., et al. (2002) · Diabetologia · doi:10.1007/s00125-002-0855-0 · Cited by 36 · see citing works

Gliclazide treatment of streptozotocin diabetic rats restores GLUT4 protein content and basal glucose uptake in skeletal muscle

Pulido, N., Suarez, A., Casanova, B., Romero, R., Rodriguez, E., & Rovira, A. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90310-3 · Cited by 35 · see citing works

Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide

Kinoshita, N., Kakehashi, A., Inoda, S., et al. (2002) · Diabetologia · doi:10.1007/s00125-002-0820-y · Cited by 33 · see citing works

Gliclazide modified release: From once-daily administration to 24-hour blood glucose control

Harrower, A. (2000) · Metabolism · doi:10.1053/meta.2000.17823 · Cited by 30 · see citing works

The mechanisms of inhibitory actions of gliclazide on neutrophils–endothelial cells adhesion and surface expression of endothelial adhesion molecules mediated by a high glucose concentration

Itoh, M., Omi, H., Okouchi, M., et al. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00219-7 · Cited by 29 · see citing works

Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury

Okayama, N., Omi, H., Okouchi, M., et al. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(02)00178-2 · Cited by 28 · see citing works

Effects of an oral antidiabetic drug on the fibrinolytic system of blood in insulin-treated diabetic patients

Gram, J., Jespersen, J., & Kold, A. (1988) · Metabolism · doi:10.1016/0026-0495(88)90150-3 · Cited by 28 · see citing works

Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: Role of initial continuous subcutaneous insulin infusion-induced normoglycemia

Casa, L. D., Rio, G. D., Gläser, B., & Cerasi, E. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90416-u · Cited by 20 · see citing works

24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily.

Guillausseau, P. J., & Greb, W. H. (2001) · PubMed · Cited by 20 · see citing works

Gliclazide potentiates suppression of hepatic glucose production in non—insulin-dependent diabetic patients

Riccio, A., LISATO, G., de Kreutzenberg, S. V., Marchetto, S., Turrin, M., Tiengo, A., & Prato, S. D. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90235-8 · Cited by 14 · see citing works

Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: The role of gliclazide

Akanuma, Y., Kosáka, K., Kanazawa, Y., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90422-t · Cited by 13 · see citing works

Diabetes mellitus: its effect on the flow properties of blood.

Oughton, J., Aj, B., & KOHNER, E. M. (1981) · PubMed · Cited by 13 · see citing works

Gliclazide Mainly Affects Insulin Secretion in Second Phase of Type 2 Diabetes Mellitus

Ligtenberg, J. J. M., Reitsma, W. D., & van Haeften, T. W. (2001) · Hormone and Metabolic Research · doi:10.1055/s-2001-15411 · Cited by 9 · see citing works

ORIGINAL ARTICLE. Differential effects of sulphonylureas on the vasodilatory response evoked by KATP channel openers

Ravel, D., Levens, N. R., Félétou, M., Neliat, G., Auclair, J., & Bouskela, E. (2003) · Fundamental and Clinical Pharmacology · doi:10.1046/j.1472-8206.2003.00144.x · Cited by 8 · see citing works

Endothelium: the main actor or choreographer in the remodelling of the retinal microvasculature in diabetes?

Tooke, J. E. (1996) · Diabetologia · doi:10.1007/bf00418549 · Cited by 8 · see citing works

Type 2 Diabetes Mellitus

Johnson, D. G., & BRESSLER, R. C. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-700-0_9 · Cited by 7 · see citing works

Does Gliclazide Stimulate First-Phase, Second-Phase, or Both Phases of Insulin Release?

Cerasi, E. (2002) · Hormone and Metabolic Research · doi:10.1055/s-2002-20526 · Cited by 2 · see citing works

Hypoglycemia in Type 2 Diabetes

Zammitt, N. N., & Frier, B. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2948 · Cited by 435 · see citing works

GUIDE study: double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patients

Schernthaner, G., Grimaldi, A., Di Mario, U., Drzewoski, J., Kempler, P., Kvapil, M., Novials, A., Rottiers, R., Rutten, G. E. H. M., & Shaw, K. M. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01381.x · Cited by 271 · see citing works

The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study)

Barnett, A. H., Krentz, A. J., Strojek, K., Sieradzki, J., Azizi, F., Embong, M., Imamoglu, S., Perušičová, J., Uličiansky, V., & Winkler, G. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00894.x · Cited by 106 · see citing works

Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea

Baksi, A., James, R., Zhou, B., & Nolan, J. J. (2004) · Acta Diabetologica · doi:10.1007/s00592-004-0146-y · Cited by 28 · see citing works

Bioavailability and Antidiabetic Activity of Gliclazide-Loaded Cubosomal Nanoparticles

Nasr, M., Almawash, S., Saqr, A. A., Bazeed, A. Y., Saber, S., & Elagamy, H. I. (2021) · Pharmaceuticals · doi:10.3390/ph14080786 · Cited by 38 · see citing works

Effect of ritonavir on the pharmacodynamics of gliclazide in animal models.

Mastan, S., & Kilari, E. K. (2009) · Diabetologia Croatica · Cited by 8 · see citing works

[Pharmacodynamics of second generation sulfonylureas: dose-effect curve of gliclazide in type 2 diabetes mellitus].

Procacci, V., Giovine, A., Roberto, M. G., et al. (1988) · PubMed · Cited by 1 · see citing works

Influence of atazanavir on the pharmacodynamics and pharmacokinetics of gliclazide in animal models

Mastan, S., & Kilari, E. K. (2009) · International Journal of Diabetes Mellitus · doi:10.1016/j.ijdm.2009.10.001 · Cited by 17 · see citing works